Wavelength News and Research

RSS

UNC-developed technique has broad applications in cancer, biomedical research

A precise understanding of cellular growth and movement is the key to developing new treatments for cancer and other disorders caused by dysfunctional cell behavior. Recent breakthroughs in genetic medicine have uncovered how genes control whether cellular proteins are turned 'on' or 'off' at the molecular level, but much remains to be understood about how protein signaling influences cell behavior.

17 May 2010

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEA-Leti today announced the launch of the TARGET-PDT project designed to increase the effectiveness of photodynamic therapy for treating cancer by developing a novel nano carrier-based approach.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Protect eyes from sun's UV rays to decrease risk of eye diseases, disorders

With summer right around the corner, more people will be spending time outdoors and UV protection will be top of mind. Unfortunately, most people think about the protection of their skin, when they should also be considering the safety of their eyes. In fact, according to the American Optometric Association's (AOA) American Eye-Q® survey, only one-third of Americans said UV protection is the most important factor they consider when purchasing sunglasses.

3 May 2010

NWO awards 31 grants in Investment Subsidy NWO Medium programme

The Netherlands Organisation for Scientific Research (NWO) has awarded 31 grants in the Investment Subsidy NWO Medium programme for the acquisition of equipment, the setting up of data collections and the production of software and bibliographies. The total investment amounts to 10 million euro.

30 Apr 2010

Bruker to supply customized N8 TITANOS large sample AFM to US Commerce Department's NIST

Bruker today announced that it has been awarded a $1.1 million contract to supply a customized N8 TITANOS™ large sample Atomic Force Microscope (AFM) to the United States Commerce Department's National Institute of Standards and Technology (NIST). The instrument will be used by NIST's Precision Engineering Division (PED) at its Manufacturing Engineering Laboratory, with a main focus on metrology applications which require traceable AFM (T-AFM).

26 Apr 2010

Handheld SD-OCT device helps examine vitreoretinal interface in infants with SBS

Ophthalmologists examining infants for possible Shaken Baby Syndrome (SBS) found that a handheld Spectral Domain Optical Coherence Tomography (SD-OCT) device provided high-resolution images of the retina and the vitreoretinal interface in infants with SBS, reports a study in the current issue of Retina, The Journal of Retinal and Vitreous Diseases.

17 Apr 2010

1440 nm wavelength beneficial in laser-assisted lipolysis for fat-disruption and tissue tightening

Cynosure, Inc. today announced the presentation of a new study that demonstrates the clinical benefits of using a 1440 nm wavelength in laser-assisted lipolysis to disrupt fat tissue and tighten skin through tissue coagulation. The study, led by Barry DiBernardo, M.D., Medical Director of New Jersey Plastic Surgery, is one of six Cynosure-related abstracts being presented this week at the 2010 American Society for Laser Medicine and Surgery (ASLMS) Annual Conference in Arizona.

16 Apr 2010

Darmstadt physicists find new method for generating tunable wavelengths

Researchers at the Technische Universität Darmstadt have found a new method for generating tunable wavelengths, as well as more easily switching back and forth between two wavelengths, employing quantum-dot lasers.

15 Apr 2010

New BD LSRFortessa Cell Analyzer delivers maximal sensitivity and resolution for multicolor applications

Building upon its powerful BD™ LSR cell analyzer platform, BD Biosciences launched today a new off-the-shelf BD LSRFortessa™ System, which uses up to four lasers -- blue, red, violet and UV -- that enable the detection of up to 18 colors simultaneously.

15 Apr 2010

Implanting blue light-filtering IOLs during cataract surgery may help preserve retina health

Implanting blue light-filtering intraocular lenses during cataract surgery helps maintain visual function and may preserve the health of the retina, specifically in disease states such as age-related macular degeneration, according to a comprehensive review published in the May/June 2010 edition of Survey of Ophthalmology.

13 Apr 2010

VisEn Medical announces launch of new GastroSense 750 fluorescence agent for imaging gastric motility

VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new GastroSense™ 750 fluorescence agent for imaging gastric motility and related drug effects in vivo.

26 Mar 2010

Ultraviolet portion of sunlight may play bigger role in controlling MS: Study

For more than 30 years, scientists have known that multiple sclerosis (MS) is much more common in higher latitudes than in the tropics. Because sunlight is more abundant near the equator, many researchers have wondered if the high levels of vitamin D engendered by sunlight could explain this unusual pattern of prevalence.

23 Mar 2010

Researchers use optogenetics technology to troubleshoot neural circuits

Recently, brain researchers have gained a powerful new way to troubleshoot neural circuits associated with depression, Parkinson's disease and other conditions in small animals such as rats. They use an optogenetics technology, invented at Stanford University, that precisely turns select brain cells on or off with flashes of light. Although useful, the optogenetics tool set has been limited.

19 Mar 2010

Researchers develop new analytical method to process large amounts of information faster

Researchers at North Carolina State University have developed a new analytical method that opens the door to faster processing of large amounts of information, with applications in fields as diverse as the military, medical diagnostics and homeland security.

17 Mar 2010

Nanoparticles provide a targeted version of photothermal therapy for cancer

In a lecture he delivered in 1906, the German physician Paul Ehrlich coined the term Zuberkugel, or "magic bullet," as shorthand for a highly targeted medical treatment.

15 Mar 2010

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.

12 Mar 2010

Nanoparticles: Targeted cancer therapy

Another weapon in the arsenal against cancer: Nanoparticles that identify, target and kill specific cancer cells while leaving healthy cells alone.

9 Mar 2010

HOYA ConBio to introduce DermaSculpt and MedLite C5 lasers at AAD Annual Meeting

HOYA ConBio, a global leader in aesthetic medical lasers, will introduce the DermaSculpt Er:YAG and the MedLite C5 Q-Switched Nd:YAG lasers at the 68th Annual Meeting of the American Academy of Dermatology, March 5-9th at the Miami Convention Center (Booth #819).

5 Mar 2010

Overview of nanotechnology: Nanoparticles may eventually be used in cosmetic products

The rapidly growing field of nanotechnology and its future use in cosmetic products holds both enormous potential and potential concern for consumers. Currently, major cosmetic manufacturers have imposed a voluntary ban on the use of nanoparticles in products while they await a ruling from the Food and Drug Administration regarding the safety of this technology.